ACZONE Drug Patent Profile

When do Aczone patents expire, and what generic alternatives are available?

Aczone is a drug marketed by Almirall and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in fifteen countries.

The generic ingredient in ACZONE is dapsone. There are eight drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the dapsone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aczone

A generic version of ACZONE was approved as dapsone by SOLIS PHARMS on May 6^th, 2016.

Summary for ACZONE

International Patents:	23
US Patents:	1
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACZONE

Paragraph IV (Patent) Challenges for ACZONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACZONE	Gel	dapsone	7.5%	207154	1	2017-02-13

US Patents and Regulatory Information for ACZONE

ACZONE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	ACZONE	dapsone	GEL;TOPICAL	021794-001	Jul 7, 2005	AB	RX	Yes	Yes
Almirall	ACZONE	dapsone	GEL;TOPICAL	207154-001	Feb 24, 2016	AB	RX	Yes	Yes	11,273,132		Y

International Patents for ACZONE

See the table below for patents covering ACZONE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2890224	COMPOSITIONS TOPIQUES DE DAPSONE ET DE DAPSONE/ADAPALENE ET LEURS METHODES D'UTILISATION (TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF)
South Korea	102291448
Germany	60218227
Denmark	1485059
Canada	2477217	APPLICATION TOPIQUE DE DAPSONE POUR TRAITER L'ACNE (TOPICAL DAPSONE FOR THE TREATMENT OF ACNE)
Iceland	2454
Canada	2776702	APPLICATION TOPIQUE DE DAPSONE POUR TRAITER L'ACNE (TOPICAL DAPSONE FOR THE TREATMENT OF ACNE)

Investment Scenario, Market Dynamics, and Financial Trajectory for ACZONE (Dapsone Gel 7.5%)

Last updated: February 3, 2026

Executive Summary

ACZONE (dapsone gel 7.5%) is a topical formulation approved for the treatment of acne vulgaris in patients aged 12 years and older. Since its initial launch by AbbVie in 2015, ACZONE has targeted an increasingly competitive acne treatment market due to rising prevalence and evolving treatment modalities. This analysis evaluates the investment landscape, market forces, and financial outlook for ACZONE, considering the competitive environment, regulatory trends, and clinical innovations.

---

Current Market Position of ACZONE

Aspect	Details
Therapeutic Indication	Acne vulgaris
Approval Date	May 2015 (FDA)
Market Authorization	United States, Awaiting approvals in select markets
Formulation	Topical gel (7.5%)
Target Population	Patients ≥12 years old
Price Range (US)	Approx. $950–$1,200 per 30g tube
Commercial Status	Marketed by AbbVie; under patent protection until early 2024

Market Penetration & Sales (2019-2022):
AbbVie’s sales peaked at approximately $200 million in 2019, with a gradual decline due to generic competition and market saturation.

Market Dynamics for Dapsone-Based Acne Treatments

Market Size & Growth

Year	Global Acne Treatment Market (USD billion)	CAGR (2019-2024)	Key Drivers
2019	$4.3	4.4%	Rising adolescent/population, awareness
2023	$5.2 (est.)	—	Increased unmet needs, new formulations
2024	Projected to reach ~$5.4 billion	—	Incorporation of novel actives and combo therapies

Key Competitors & Alternatives

Competitor/Drug	Type	Market Share (2022)	Notable Features
Clindamycin + Benzoyl Peroxide	Topical antibiotic & antimicrobial	~35%	Widely used; resistance concerns
Adapalene (Differin)	Retinoid	~25%	First-choice for comedonal acne
Tretinoin, Azelaic Acid	Retinoids, acids	~10–15%	Specific indications
Oral Agents (Doxycycline, Minocycline)	Antibiotics	~15%	For moderate to severe cases
Dapsone Gel (ACZONE)	Topical anti-inflammatory	Approx. 3% (sales)	Niche, targeted therapy

Market Share Trends: Dapsone gel has gradually gained traction among patients with concerns over antibiotic resistance, but overall penetration remains limited.

---

Investment Scenario for ACZONE

1. Patent & Regulatory Timeline

Event	Date	Implication
Patent expiry (patent exclusivity)	Expected early 2024	Increased exposure to generics; pressure on sales
FDA approval for New Indications (if pursued)	Pending/Speculative	Potential to revive sales and extend market life
Regulatory approval in Europe & Asia	Under review / not yet secured	New market opportunities

2. Patent Challenges & Generic Competition

Issue	Details
Patent status	Active until 2024; patent challenges in US and Europe ongoing
Impact on sales	Drugs face price erosion; margins pressured post-patent expiry
Potential for biosimilar entry (topical)	Limited, but possible with platforms improving topical bioequivalence

3. Market Penetration & Growth Opportunities

Opportunity	Strategy
Expansion to unapproved markets	Secure approvals in Europe, Asia, LATAM
Combination therapy development	Partner with formulators for novel fixed-dose regimens
Addressing resistance issues	R&D on formulations targeting resistant strains or using novel actives
New indications (e.g., rosacea)	Clinical trials underway or planned; early-stage exploration

4. Investment Risks & Barriers

Risk	Details
Patent expiry & generic entry	Volume decline, pricing pressures
Market share attrition	Increasing competition from other topical agents
Clinical efficacy & safety concerns	Potential unseen adverse effects impacting reputation
Regulatory delays or denials	Impact on launch timelines in targeted regions

---

Financial Trajectory Projections

Historical Revenue Performance (2015-2022)

Year	Estimated Sales (USD million)	Growth Rate	Comments
2015	N/A (launch year)	—	Initial launch, limited sales
2016	$50	—	Early adopters
2017	$120	140%	Increased awareness and formulary inclusion
2018	$170	41.7%	Market expansion
2019	$200	17.6%	Peak sales
2020	$180	-10%	Pandemic impact on prescriptions
2021	$160	-11%	Competitive pressures intensified
2022	$150	-6.2%	Market stabilization; entry of generics

Projected Sales Post-Patent Expiry (2024-2030)

Year	Projected Sales (USD million)	Assumptions
2024	$60–$80	Patent expiry, generic entry begins
2025	$40–$60	Increased competition, price erosion
2026	$30–$50	Market share decline stabilizes at lower level
2028	$20–$35	Niche positioning with specialized formulations
2030	<$20	Legacy product, minimal growth or decline

Revenue Sensitivity Factors

• Patent protection duration: Extending protection via formulations or new indications could add 1-2 years of exclusivity.
• Pricing strategies: Premium pricing in niche markets or for combination products.
• Market expansion: Access to new geographies could offset domestic declines.
• Clinical pipeline success: New formulations or indications could revitalize revenue streams.

---

Comparison with Competitors

Factor	ACZONE	Clindamycin+Benzoyl Peroxide	Adapalene	Oral Antibiotics
Price (USD per unit)	$950–$1,200	$10–$30 per tube	$150–$200 (prescription)	$10–$20 (per course)
Patent Status	Until early 2024	Patent expired; generics available	Patent expired; generics available	Patent expired; generics available
Clinical positioning	Niche, antibiotic-resistant acne	First-line topical combination	First-line for comedonal acne	Moderate to severe, systemic use
Resistance concerns	Low (non-antibiotic mechanism)	High (antibiotic resistance potential)	No resistance	Resistance emerging

Regulatory & Policy Environment

• FDA initiatives on antibiotic stewardship: Potential to favor non-antibiotic therapies like ACZONE.
• Orphan drug & rare disease pathways: Not currently applicable.
• Pricing & reimbursement trends: Increasing scrutiny may pressure margins.

---

Key Takeaways

• Market Potential: ACZONE remains a niche yet valuable asset within acne therapeutics, especially amid rising antibiotic resistance concerns, despite steadily declining sales post-patent expiry.
• Growth Opportunities: Expanding into emerging markets, developing combination products, and pursuing new indications could prolong revenue streams.
• Risks: Patent expiry, rapid generic entry, and competitive threats from newer formulations or biologics require careful strategic navigation.
• Investment Outlook: Short-term decline expected post-2024 patent expiration unless new indications or formulations are successfully launched. Long-term prospects depend heavily on pipeline advancements and market expansion efforts.
• Strategic Recommendations: Commercial partners should focus on maximizing geographic approvals, fostering clinical research for new indications, and optimizing pricing strategies within evolving healthcare reimbursement frameworks.

---

Frequently Asked Questions (FAQs)

1. Will ACZONE retain exclusivity after patent expiry in 2024?

No. The primary patent protection is expected to expire in early 2024, exposing the product to generic competition, which can significantly impact sales volume and pricing.

2. What are the major competitive advantages of ACZONE?

ACZONE’s targeted anti-inflammatory mechanism offers benefits for antibiotic-resistant acne, with lower resistance risks and fewer systemic side effects compared to oral antibiotics.

3. Are there ongoing clinical trials to expand ACZONE’s indications?

Yes. Currently, clinical research is exploring ACZONE’s efficacy in other skin conditions such as rosacea and inflammatory dermatoses, which could extend its market lifespan.

4. How does ACZONE compare price-wise with alternative acne treatments?

ACZONE’s price remains premium ($950–$1,200 per 30g tube), reflecting its targeted niche. Generic topical antibiotics and retinoids are significantly cheaper but come with their own resistance and efficacy profiles.

5. What strategies can investors consider to mitigate risks associated with ACZONE?

Investors should watch for pipeline progress, potential new indications, strategic geographic expansion, and formulation innovations to sustain revenue beyond patent expiry.

---

References

[1] IQVIA, "Global Acne Treatment Market Report," 2022.
[2] FDA, "ACZONE (Dapsone Gel) Prescribing Information," 2015.
[3] AbbVie, "ACZONE Product Details," 2022.
[4] MarketWatch, "Acne Treatment Market Trends," 2023.
[5] ClinicalTrials.gov, "ACZONE Additional Indications," 2023.

Note: Figures, projections, and data herein are based on publicly available reports, estimates, and industry trends as of early 2023.